All In MedTech

Device Trial Radar · NCT04358003

Plasma Adsorption in Patients With Confirmed COVID-19

Plasma Adsorption in Patients With Confirmed COVID-19 Infection

Last checked: Nov 20, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

107

Actual

Start

May 20, 2020

Primary completion

Nov 26, 2021

Study completion Apr 1, 2022

Sponsor

Lead sponsor
Marker Therapeutics AGNot on our public-company list
Sponsor type
Industry
Collaborators
Terumo BCT
First posted
Apr 22, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.

Conditions

  • Respiratory Failure
  • ARDS

Interventions

  • Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)Device

    Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected. Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: Day 28

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences (UAMS)

    Little Rock, Arkansas

  • UNM Health Science Center

    Albuquerque, New Mexico

  • Providence Portland Medical Center

    Portland, Oregon

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.